Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India

  • Doval, Dinesh Chandra (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Suresh, P (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Sinha, Rupal (Department of Research, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Azam, Saud (Department of Research, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Batra, Ullas (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Talwar, Vineet (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Kumar, Kapil (Department of Surgical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Mehta, Anurag (Department of Laboratory Services, Rajiv Gandhi Cancer Institute & Research Centre)
  • Published : 2016.06.01


Background: Triple-negative breast cancer (TNBC) often presents as an interval cancer with short survival upon metastasis and thus represents an important clinical challenge. The present study investigated the clinicopathologic characteristics and long term survival outcome of early and locally advanced TNBC. Materials and Methods: Medical records were reviewed retrospectively for 148 consecutive confirmed cases of TNBC treated in a single unit at our centre. Demographic profile, tumor type, histopathology details, treatment and follow-up information was recorded and immunohistochemistry was performed. Results: Age group >50 years was associated with tumors of clinical stage 3 (53.8%), pathological stage 3 (46.2%), pathological grade 3 (45.7%), presence of extracapsular extension (ECE, 48.5%) and lymphovascular invasion (LVI, 64.9%). Locally advanced breast cancers (LABCs) were characterized by pathological stage 3 (96.2%), presence of ECE (100%) and absence of LVI (46.7%) as compared to early breast cancers (EBCs) which had higher incidence of lower stage tumors (100%), absence of ECE (82%) and presence of LVI (91.9%; p-value <0.001. Better relapse free survival was observed in patients with no axillary involvement (69%; p-value <0.001) and absence of ECE (64%; p-value <0.001). Improved overall survival was seen in patients with EBC (90%; p-value 0.008), clear axilla (86%; p-value <0.001), absence of ECE (87%; p-value <0.001) and negative lymph nodes (90%; p-value 0.006). Conclusions: TNBCs are aggressive tumors which show poor long term survival. Patients with TNBC benefit from chemotherapy, thus better and less toxic treatment options are needed. Identification of newer targets and development of targeted therapies are the need of the hour.


  1. Cetin I, Topcul M (2014). Triple negative breast cancer. Asian Pac J Cancer Prev, 15, 2427-31. https://doi.org/10.7314/APJCP.2014.15.6.2427
  2. Dawood S, Broglio K, Kau SW, et al (2009). Triple receptornegative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol, 27, 220-6. https://doi.org/10.1200/JCO.2008.17.9952
  3. Demicheli R, Bonadonna G, Hrushesky WJ, et al (2004). Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res, 6, 689-96. https://doi.org/10.1186/bcr937
  4. Fisher B, Brown AM, Dimitrov NV, et al (1990). Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical adjuvant Breast and Bowel Project B-15. J Clin Oncol, 8, 1483-96. https://doi.org/10.1200/JCO.1990.8.9.1483
  5. Foulkes WD, Smith IE, Reis-Filho JS (2010). Triple-negative breast cancer. N Engl J Med, 363, 1938-48. https://doi.org/10.1056/NEJMra1001389
  6. Hudis CA, Gianni L (2011). Triple-negative breast cancer: an unmet medical need. Oncol, 16, 1-11.
  7. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  8. Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81. https://doi.org/10.1080/01621459.1958.10501452
  9. Keam B, Im SA, Kim HJ, et al (2007). Prognostic impact of clinicopathological parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer, 7, 203. https://doi.org/10.1186/1471-2407-7-203
  10. Kong M, Hong SE (2013). Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis? Cancer Res Treat, 45, 103-11. https://doi.org/10.4143/crt.2013.45.2.103
  11. Krishnamurthy S, Poornima R, Challa VR, et al (2012). Triple negative breast cancer - our experience and review. Indian J Surg Oncol, 3, 12-6. https://doi.org/10.1007/s13193-012-0138-2
  12. Li CY, Zhang S, Zhang XB, et al (2013). Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev, 14, 3779-84. https://doi.org/10.7314/APJCP.2013.14.6.3779
  13. Liedke C, Mazouni C, Hess KR, et al (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-81. https://doi.org/10.1200/JCO.2007.14.4147
  14. Malorni L, Shetty PB, De Angelis C, et al (2012). Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat, 136, 795-804. https://doi.org/10.1007/s10549-012-2315-y
  15. Ovcaricek T, Frkovic SG, Matos E, et al (2011). Triple negative breast cancer - prognostic factors and survival. Radiol Oncol, 45, 46-52.
  16. Quiet CA, Ferguson DJ, Weichselbaum RR, et al (1995). Natural history of node negative breast cancer, a study of 826 patients with long term follow up. J Clin Oncol, 13, 1144-51. https://doi.org/10.1200/JCO.1995.13.5.1144
  17. Rhee J, Han SW, Oh DY, et al (2008). The clinicopathologic characteristics and prognostic significance of triplenegativity in node-negative breast cancer. BMC Cancer, 8, 307. https://doi.org/10.1186/1471-2407-8-307
  18. Roche H, Fumoleau P, Spielmann M, et al (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol, 24, 5664-71. https://doi.org/10.1200/JCO.2006.07.3916
  19. Sen S, Gayen R, Das S, et al (2012). A clinical and pathological study of triple negative breast carcinoma: experience of a tertiary care centre in eastern India. J Indian Med Assoc, 110, 686-9.
  20. Sharma B, Satyanarayan, Kalwar A, et al (2013). Five year retrospective survival analysis of triple negative breast cancer in North-West India. Indian J Cancer, 50, 330-2. https://doi.org/10.4103/0019-509X.123616
  21. Suresh P, Batra U, Doval DC (2013). Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India. Indian J Med Paediatr Oncol, 34, 89-95. https://doi.org/10.4103/0971-5851.116185
  22. Tian XS, Cong MH, Zhou WH, et al (2008). Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie, 31, 610-4.
  23. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.